{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:11:52Z","timestamp":1789726312084,"version":"4.0.1"},"reference-count":18,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2017,8,22]],"date-time":"2017-08-22T00:00:00Z","timestamp":1503360000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2018,1]]},"abstract":"\n Aims<\/jats:title>\n \n To simplify administration of aqueous exenatide once weekly, which requires reconstitution, the exenatide microspheres have been reformulated in a ready\u2010to\u2010use autoinjector with a\n M<\/jats:styled-content>\n iglyol diluent (exenatide\n QWS\u2010AI<\/jats:styled-content>\n ). This study compared the efficacy and safety of exenatide\n QWS\u2010AI<\/jats:styled-content>\n with the first\u2010in\u2010class glucagon\u2010like peptide\u20101 receptor agonist exenatide twice daily (\n BID<\/jats:styled-content>\n ).\n <\/jats:p>\n <\/jats:sec>\n \n \n Materials and\n M<\/jats:styled-content>\n ethods\n <\/jats:title>\n \n This randomized, open\u2010label, controlled study in patients with type 2 diabetes using diet and exercise or taking stable oral glucose\u2010lowering medication randomized patients 3:2 to either exenatide\n QWS\u2010AI<\/jats:styled-content>\n (2\u2009mg) or exenatide BID (10\u2009\u03bcg) for 28\u2009weeks. The primary outcome was the 28\u2010week change in glycated haemoglobin (\n HbA1c<\/jats:styled-content>\n ). A subset of patients completed a standardized meal test for postprandial and pharmacokinetic assessments.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 375 patients (mean\n HbA1c<\/jats:styled-content>\n , 8.5% [69\u2009mmol\/mol]; body mass index, 33.2\u2009kg\/m\n 2<\/jats:sup>\n ; diabetes duration, 8.5\u2009years) received either exenatide\n QWS\u2010AI<\/jats:styled-content>\n (n\u2009=\u2009229) or exenatide\n BID<\/jats:styled-content>\n (n\u2009=\u2009146);\n HbA1c<\/jats:styled-content>\n was reduced by \u22121.4% and \u22121.0%, respectively (least\u2010squares mean difference, \u22120.37%;\n P<\/jats:italic>\n \u2009=\u2009.0072). More patients achieved\n HbA1c<\/jats:styled-content>\n \u2009<7.0% with exenatide\n QWS\u2010AI<\/jats:styled-content>\n (49.3%) than with exenatide\n BID<\/jats:styled-content>\n (43.2%;\n P<\/jats:italic>\n \u2009=\u2009.225). Body weight was reduced in both groups (\n P<\/jats:italic>\n \u2009=\u2009.37 for difference). Gastrointestinal adverse events (\n AE<\/jats:styled-content>\n s) were reported in 22.7% (exenatide\n QWS\u2010AI<\/jats:styled-content>\n ) and 35.6% (exenatide\n BID<\/jats:styled-content>\n ) of patients; fewer patients in the exenatide\n QWS\u2010AI<\/jats:styled-content>\n group withdrew because of\n AE<\/jats:styled-content>\n s than in the exenatide\n BID<\/jats:styled-content>\n group. Minor hypoglycaemia occurred most often with concomitant sulfonylurea use.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n Exenatide\n QWS\u2010AI<\/jats:styled-content>\n was associated with a greater reduction in\n HbA1c<\/jats:styled-content>\n , similar weight loss and a favorable gastrointestinal\n AE<\/jats:styled-content>\n profile compared with exenatide\n BID<\/jats:styled-content>\n .\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/dom.13056","type":"journal-article","created":{"date-parts":[[2017,7,7]],"date-time":"2017-07-07T09:39:16Z","timestamp":1499420356000},"page":"165-172","source":"Crossref","is-referenced-by-count":35,"title":["Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes"],"prefix":"10.1111","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3056-0047","authenticated-orcid":false,"given":"Carol H.","family":"Wysham","sequence":"first","affiliation":[{"name":"Rockwood Clinic Spokane Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Rosenstock","sequence":"additional","affiliation":[{"name":"Dallas Diabetes Research Center at Medical City Dallas Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion L.","family":"Vetter","sequence":"additional","affiliation":[{"name":"Bristol\u2010Myers Squibb Princeton New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Dong","sequence":"additional","affiliation":[{"name":"AstraZeneca Gaithersburg Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"\u00d6hman","sequence":"additional","affiliation":[{"name":"AstraZeneca Gaithersburg Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nayyar","family":"Iqbal","sequence":"additional","affiliation":[{"name":"AstraZeneca Gaithersburg Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,8,22]]},"reference":[{"key":"e_1_2_6_2_1","unstructured":"BYDUREON (Exenatide Extended\u2010Release) for Injectable Suspension: US Prescribing Information. Wilmington Delaware: AstraZeneca Pharmaceuticals LP;2017.https:\/\/www.azpicentral.com\/bydureon\/pi_bydureon.pdf#page=1. Accessed June 28 2017."},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.2165\/11585880-000000000-00000"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2015.01.008"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2016.0107"},{"key":"e_1_2_6_6_1","unstructured":"BYETTA (Exenatide) Injection: US Prescribing Information. Wilmington Delaware: AstraZeneca Pharmaceuticals LP;2015.https:\/\/www.azpicentral.com\/byetta\/pi_byetta.pdf#page=1. Accessed June 28 2017."},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01561.x"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2012.140"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-1609"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61206-4"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-2081"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60659-0"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-0366"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2760"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/157201"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0126769"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12872"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60479-6"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2012.0144"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.13056","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.13056","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.13056","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.13056","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T04:57:49Z","timestamp":1761886669000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.13056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,22]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["10.1111\/dom.13056"],"URL":"https:\/\/doi.org\/10.1111\/dom.13056","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,22]]}}}